Mylan EPS - Earnings per Share 2006-2018 | MYL

Mylan annual and quarterly earnings per share history from 2006 to 2018. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Mylan EPS for the quarter ending June 30, 2018 was $0.07, a 87.27% decline year-over-year.
  • Mylan EPS for the twelve months ending June 30, 2018 was $0.87, a 29.27% decline year-over-year.
  • Mylan 2017 annual EPS was $1.3, a 41.3% increase from 2016.
  • Mylan 2016 annual EPS was $0.92, a 45.88% decline from 2015.
  • Mylan 2015 annual EPS was $1.7, a 27.35% decline from 2014.
Mylan Annual EPS
2017 $1.30
2016 $0.92
2015 $1.70
2014 $2.34
2013 $1.58
2012 $1.52
2011 $1.22
2010 $0.68
2009 $0.30
2008 $-1.10
2007 $-4.53
2007 $0.99
2006 $0.79
2005 $0.74
Mylan Quarterly EPS
Q2 2018 $0.07
Q1 2018 $0.17
Q4 2017 $0.47
Q3 2017 $0.16
Q2 2017 $0.55
Q1 2017 $0.12
Q4 2016 $0.79
Q3 2016 $-0.23
Q2 2016 $0.33
Q1 2016 $0.03
Q4 2015 $0.42
Q3 2015 $0.83
Q2 2015 $0.32
Q1 2015 $0.13
Q4 2014 $0.47
Q3 2014 $1.26
Q2 2014 $0.32
Q1 2014 $0.29
Q4 2013 $0.45
Q3 2013 $0.40
Q2 2013 $0.46
Q1 2013 $0.27
Q4 2012 $0.38
Q3 2012 $0.51
Q2 2012 $0.33
Q1 2012 $0.30
Q4 2011 $0.30
Q3 2011 $0.36
Q2 2011 $0.33
Q1 2011 $0.23
Q4 2010 $-0.01
Q3 2010 $0.33
Q2 2010 $0.16
Q1 2010 $0.20
Q4 2009 $0.01
Q3 2009 $-0.13
Q2 2009 $0.19
Q1 2009 $0.23
Q4 2008 $-0.05
Q3 2008 $0.47
Q2 2008 $-0.05
Q1 2008 $-1.47
Q4 2007 $-5.14
Q3 2007 $0.60
Q2 2007 $0.32
Q1 2007 $-0.31
Q4 2006 $0.63
Q3 2006 $0.36
Q2 2006 $0.35
Q1 2006 $0.00
Q4 2005 $0.22
Q3 2005 $0.16
Q2 2005 $0.16
Q1 2005 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $17.070B $11.908B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $63.812B 10.95
Teva Pharmaceutical Industries (TEVA) Israel $22.636B 6.32
Bausch Health Cos (BHC) Canada $9.063B 6.75
Dr Reddy's Laboratories (RDY) India $5.840B 26.09
Supernus Pharmaceuticals (SUPN) United States $2.522B 26.99
Mallinckrodt Public (MNK) United Kingdom $2.316B 3.94
Amphastar Pharmaceuticals (AMPH) United States $0.862B 124.20
Akorn (AKRX) United States $0.842B 0.00
Homology Medicines (FIXX) United States $0.751B 0.00
CymaBay Therapeutics (CBAY) United States $0.654B 0.00
Assembly Biosciences (ASMB) United States $0.652B 0.00
Voyager Therapeutics (VYGR) United States $0.519B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.517B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.475B 0.00
Corium (CORI) United States $0.456B 0.00
Teligent (TLGT) United States $0.179B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.133B 0.00
Sol-Gel Technologies (SLGL) Israel $0.125B 0.00
Aevi Genomic Medicine (GNMX) United States $0.069B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.062B 0.00
Evoke Pharma (EVOK) United States $0.045B 0.00
Acasti Pharma (ACST) Canada $0.044B 0.00
Agile Therapeutics (AGRX) United States $0.034B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.011B 0.00
China Pharma Holdings (CPHI) China $0.011B 0.00